Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293479" target="_blank" >RIV/00064203:_____/14:10293479 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10293479

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189222/" target="_blank" >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189222/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/openhrt-2014-000134" target="_blank" >10.1136/openhrt-2014-000134</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban

Popis výsledku v původním jazyce

Apixaban is the third novel oral anticoagulant approved by the Food and Drug Administration for the reduction in the risk of stroke in patients with atrial fibrillation. Apixaban showed a significant reduction in mortality as well as a reduction in strokes compared with warfarin in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.1 However, it is unclear how much of this 'benefit' was derived from the negative benefit to risk ratio (RR) when combining aspirin with warfarin compared with warfarin alone. Approximately one-third of patients received combination warfarin-acetylsalicylic acid (ASA) therapy in ARISTOTLE at baseline (31.3% on apixaban, 30.5% on warfarin), with approximately 20-25% of patients receiving aspirin with long-term anticoagulation,2 despite the fact that only 14% of patients randomised to warfarin had a definitive indication for concomitant aspirin therapy (ie, patients having a previous myocardial infarct

Název v anglickém jazyce

Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban

Popis výsledku anglicky

Apixaban is the third novel oral anticoagulant approved by the Food and Drug Administration for the reduction in the risk of stroke in patients with atrial fibrillation. Apixaban showed a significant reduction in mortality as well as a reduction in strokes compared with warfarin in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.1 However, it is unclear how much of this 'benefit' was derived from the negative benefit to risk ratio (RR) when combining aspirin with warfarin compared with warfarin alone. Approximately one-third of patients received combination warfarin-acetylsalicylic acid (ASA) therapy in ARISTOTLE at baseline (31.3% on apixaban, 30.5% on warfarin), with approximately 20-25% of patients receiving aspirin with long-term anticoagulation,2 despite the fact that only 14% of patients randomised to warfarin had a definitive indication for concomitant aspirin therapy (ie, patients having a previous myocardial infarct

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Open Heart

ISSN

2053-3624

e-ISSN

—

Svazek periodika

1

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—